Neurological Assessment for Multiple Sclerosis and Extended Disability Scale Score

Similar documents
Guideline for the use of beta-interferons in patients with multiple sclerosis a South African proposal

ORIGINAL CONTRIBUTION. Multiple Sclerosis That Is Progressive From the Time of Onset

PATIENT INFORMATION: Patient Surname First Name Middle Initial Sex Date of Birth Alberta Personal Health Number M / F Year Month Day

Endpoints in a treatment trial in NMO: Clinician s view. Anu Jacob Consultant Neurologist The Walton Centre, Liverpool,UK

Hot Topics Multiple Sclerosis. Natalie Parks, MD, FRCPC Assistant Professor, Dalhousie University June 27, 2018

For all requests for Multiple Sclerosis Medications all of the following criteria must be met:

Multiple Sclerosis (MS) is a

CHAIR SUMMIT 7TH ANNUAL #CHAIR2014. Master Class for Neuroscience Professional Development. September 11 13, Westin Tampa Harbour Island

Multiple Sclerosis. By: Selena Fucci April 22, 2016

Multiple Sclerosis vs Acute Disseminated Encephalomyelitis in Childhood

Rapid Recovery Hyperbarics 9439 Archibald Ave. Suite 104 Rancho Cucamonga CA,

Critical Illness Claim Doctor s Statement Motor Neurone Disease

Demyelinating Diseases: Multiple Sclerosis January 10, 2018 Dr. Ostrow

Attending Physician Statement- Benign Brain Tumour or Subdural Haematoma

What is Multiple Sclerosis? Gener al information

MULTIPLE SCLEROSIS PROFILE

FORM ID. Patient's Personal Details. SECTION A : Medical Record of the Patient. Name. Policy Number. NRIC/Old IC/Passport/Birth Cert/Others

Clinical and research application of MRI in diagnosis and monitoring of multiple sclerosis

Suspected spinal cord compression form

Pediatric acute demyelinating encephalomyelitis in Denmark: a nationwide population-based study

Depression management: Emotional Disorders in Multiple Sclerosis

Myelitis. Case 2. History. Examination. Mahtab Ghadiri

MRI in Differential Diagnosis. CMSC, June 2, Jill Conway, MD, MA, MSCE

MULTIPLE SCLEROSIS - REVIEW AND UPDATE

Diagnostic Criteria, Clinical Courses, and Rating Scales in MS

Program Highlights. A multidisciplinary AAN working group identified areas for improvement in the diagnosis and management of patients with MS

Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Neuromyelitis Optica in Singapore

NEW DIAGNOSTIC CRITERIA FOR MULTIPLE SCLEROSIS

COPYRIGHT 2012 THE TRANSVERSE MYELITIS ASSOCIATION. ALL RIGHTS RESERVED

Circle Yes or No Y N. [If no, skip to question 8.] 2. Has the patient been compliant with therapy as verified by the prescriber?

Worker s Compensation Form

ATTENDING PHYSICIAN'S STATEMENT BENIGN BRAIN TUMOUR / SURGICAL REMOVAL OF PITUITARY TUMOUR OR SURGERY FOR SUBDURAL HAEMATOMA

New Insights on Optic Neuritis in Young People

Neuromyelitis optica (NMO), or Devic s disease, is a rare

Idiopathic Inflammatory Demyelinating Diseases of the Brainstem

MULTIPLE SCLEROSIS IN Managing the complexity of multiple sclerosis. Olga Ciccarelli and Alan Thompson

PMH: No medications; Immunizations UTD No hospitalizations or surgeries Speech Delay. Birth Hx: 24 WGA, NICU x6 months

Analysis of prognostic significance of clinical and paraclinical indices in case of different types of acute disseminated encephalomyelitis course.

Soliris in NMOSD Phase 3 PREVENT Study Topline Results September 24, 2018

Fast Facts: Multiple Sclerosis

MS Treatments Aubagio TM

APPENDIX D SASKATCHEWAN MS DRUGS PROGRAM

ATTENDING PHYSICIAN'S STATEMENT BACTERIAL MENINGITIS

Innovation immunomodulatory treatment case study of men diagnosed with relapsing-remitting multiple sclerosis (MS)

MEDIA BACKGROUNDER. Multiple Sclerosis: A serious and unpredictable neurological disease

Epidemiology. Geographical distribution: Average onset age: years

RSR RSR RSR RSR RSR. ElisaRSR AQP4 Ab RSR. Aquaporin-4 Autoantibody Assay Kit

Magnetic Resonance Imaging of Neuromyelitis Optica (Devic s Syndrome)

Relapses Matter A GUIDE TO REPORTING MULTIPLE SCLEROSIS SYMPTOMS

Vague Neurological Conditions

quantified neurological examination and assessment of Kurtzke s Functional Systems and Expanded Disability Status Scale in Multiple Sclerosis Exposé

Worksheet 3: Physician Medical Information Worksheet

Progress in MS: Current and Emerging Therapies. Presented by: Dr. Kathryn Giles, MD MSc FRCPC Cambridge, Ontario, Canada

Attending Physician Statement- Stroke

TECFIDERA (dimethyl fumarate) oral capsule

Multiple Sclerosis. Biology 12 Nervous System Project

Table e-1: Patient Level Baseline Characteristics

Research Example Aliza Ben-Zacharia DrNP, ANP

ORIGINAL CONTRIBUTION. Infratentorial Lesions Predict Long-term Disability in Patients With Initial Findings Suggestive of Multiple Sclerosis

PATIENTS WITH MULTIPLE SCLEROSIS

International IBD Genetics Consortium

MDWISE PRIOR AUTHORIZATION CRITERIA TYSABRI (natalizumab): 300mg/15mL single use vial

DISORDERS OF THE SPINE TREATING PHYSICIAN DATA SHEET

Neurophysiology in diagnosis and monitoring of MS

AFFIRM IN FOCUS AN INTERACTIVE OVERVIEW START HERE

Clinically Isolated Syndrome of Early Onset Multiple Sclerosis in a Sample of Iraqi Patients

ORIGINAL CONTRIBUTION. Long-term Follow-up of Acute Partial Transverse Myelitis

Diagnosis and Monitoring of Patients With Multiple Sclerosis

MULTIPLE SCLEROSIS Update

Reporting Autoimmune Diseases in Hematopoietic Stem Cell Transplantation

CNS demyelination and quadrivalent HPV vaccination

DOWNLOAD OR READ : MULTIPLE SCLEROSIS THE HISTORY OF A DISEASE PDF EBOOK EPUB MOBI

Current Enrolling Clinical Trials

ATTENDING PHYSICIAN'S STATEMENT MAJOR HEAD TRAUMA / FACIAL RECONSTRUCTIVE SURGERY / CERVICAL SPINAL CORD INJURY

Citation for published version (APA): Zwanikken, C. P. (1997). Multiple sclerose: epidemiologie en kwaliteit van leven s.n.

Kaspar Rufibach Methods, Collaboration, and Outreach Group (MCO) Department of Biostatistics, Roche Basel

ACCIDENT CLAIM DOCTOR S STATEMENT

Signature of student Date Signature of parent or guardian (if student is a minor) Date

THE NATURAL HISTORY OF MS: DIAGNOSIS, CLINICAL COURSE, AND EPIDEMIOLOGY

Multiple sclerosis in Japan: Nationwide surveys over 30 years

THE NATURAL HISTORY OF MS: DIAGNOSIS, CLINICAL COURSE, AND EPIDEMIOLOGY

Positive Phase III results for Roche s investigational medicine OCREVUS (ocrelizumab) published in New England Journal of Medicine

Multiple sclerosis. Tünde Csépány MD. PhD. 08. November 2017.

Clinical, Laboratory and Radiological Predictors of Outcome in Relapsing Remitting Multiple Sclerosis

Neuroimaging and Other Biomarkers. MRI for Diagnosis, Prognosis and Treatment Decisions in MS

Spinal cord disease in women with ALD

Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors

Carolyn Taylor, M.D. Swedish Neuroscience Center

Optic neuritis. Information for patients Ophthalmology

Frequently Asked Questions For persons with multiple sclerosis

Choices. Types of MS. Read me

Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association

Mitzi Joi Williams, MD Neurologist MS Center of Atlanta Atlanta, GA

Disclosures. Biogen Idec Novartis Acorda Genzyme Roche Pfizer

Attending Physician Statement- Severe Myasthenia Gravis

Multiple sclerosis. Tünde Csépány MD. PhD

Roche s OCREVUS (ocrelizumab) approved in Switzerland for primary progressive and relapsing forms of multiple sclerosis

AUBMC Multiple Sclerosis Center

First clinical attack of inflammatory or demyelinating disease in the CNS. Alteration in consciousness ranging from somnolence or coma

The Role of MRI in Multiple Sclerosis

Transcription:

Neurological Assessment for Multiple Sclerosis and Extended Disability Scale Score This section should only be completed by a neurologist or MD / ROD (Medical Doctor / Resident on Duty) involved in the care of the person. If you are not the person s neurologist or physician please leave this section blank. If you are the person s neurologist or physician please complete this section on each person notified. Full Name of person completing this form (Your name): (Complete in full for the first patient you notify to us thereafter we only require your name, or stamp and the date.) Date Form Completed: Address: Phone Number : (Area Code) Number E-mail Address: Designation: Neurological Assessment 1. Year of MS Diagnosis 2. Year of onset of 1 st symptoms EDSS Form 2006 03 08 1

3. Nature of 1 st symptoms ((please tick one box only) Optic neuritis Spinal cord Brainstem/cerebellar Sensory only Polysymptomatic Other please state 4. Type of MS (please tick one box only) Single demyelinating event Relapsing/Remitting Secondary Progressive Progressive since onset Not MS 5. How has the diagnosis been confirmed at any stage? Please include all events and tests performed up to and including March 6 th 2006 (please tick the appropriate box or boxes) a) Relapses 2 or more attacks. (Symptoms lasting (Greater than 30 days apart) more than 24 hrs) Or Single attack EDSS Form 2006 03 08 2

b) Progressive Greater than or equal to 12 months Neurological Signs (include both primary or Or secondary progression Less than 12 months c) Clinical signs Single clinical lesion Or 2 or more separate clinical lesions d) Oligoclonal Not done Positive Negative Bands e) Visual Evoked Not done Abnormal Normal Potentials f) MRI Not Consistent with Consistent with Normal Done demyelination demyelination single lesion 2 or more lesions Brain Spinal Cord 6. Has the patient been assessed in the last 12 months? Yes. Please go to Question 7. No. No more questions thank you. EDSS Form 2006 03 08 3

7. At the time of the last assessment which of the following best fits the patient s level of disability. (Please do not include assessments done at the time of a relapse. If only assessed at the time of a relapse please leave this question blank). Date of neurological assessment 0. Normal findings on neurological examination 1. No disability. Minimal signs on neurological examination. 2. Minimal and non ambulation-related disability. Able to run. 3. Unlimited walking distance without rest, but unable to run; or a significant non ambulation-related disability. 4. Walk without aid. Limited walking distance but greater than or equal to 500 metres without rest. 5 Walks without aid. Walking distance less than 500 metres 6A. Walks with permanent unilateral supported less than 100 metres without resting. 6B. Walks with permanent bilateral support less than 100 metres without resting. 7. Home restricted. A few steps with wall or furniture assistance. Walking distance less than 20 metres. 8. Chair restricted. Unable to take a step. Some effective use of upper limbs. 9. Bedridden and totally helpless. 10. Death due to MS EDSS Form 2006 03 08 4

8. If completed in the last 12 months please indicate the patients Extended Disability Scale Score. (See attached sheet). (Please do not include assessments done at the time of a relapse. If only assessed at the time of a relapse please leave this question blank). Date of latest EDSS assessment EDSS. Thank you for completing this form EDSS Form 2006 03 08 5